In short
Clinical trials are investigating RP3 in people with cancer, including metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma. The study data focus on long-term safety and delayed side effects in patients who were previously treated with RP3 or related RPx products. These trials help researchers understand how safe RP3 is over time.
Key points
- Clinical trials of RP3 are focused on long-term safety in patients who were previously treated with RP3 or related RPx products. The study includes people with metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma. It is a Phase 3 interventional trial with 76 participants. Researchers are mainly looking for delayed adverse events, including new cancers, neurologic problems, autoimmune disorders, blood disorders, infections, and herpetic infection. The trial is authorised and is designed to understand safety over time.
Clinical trial overview
The available trial for RP3 is an interventional study, which means participants were followed as part of a planned research program. The study is authorised and has 76 planned participants.
This trial is designed to evaluate long-term safety after treatment with RP3 or related RPx products. The brief summary says the goal is to identify delayed adverse events linked to treatment.
Who the study is for
The study includes patients with metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma. These are cancer groups that reflect the target population in the trial data.
The trial title states that the patients had been previously treated with RP1, RP2, or RP3. That means the study is focused on people after earlier treatment, not on first-time use.
Trial phase and study design
This study is in Phase 3. Phase 3 trials are later-stage studies that usually include more patients and help researchers learn more about safety in a wider group.
The study uses RP3 and related RPx products given by intratumoral use, which means the product is placed directly into the tumor. The source data list RP3, RP2, and vusolimogene oderparepvec in the intervention field.
What the researchers are measuring
The main outcome is the evaluation of delayed adverse events. These are side effects or health problems that appear later, after treatment has already been given.
Researchers are looking for several specific problems, including new malignancies, worsening or new neurologic disorders, rheumatologic or other autoimmune disorders, hematologic disorders, infection related to RPx, and herpetic infection. They are also checking for the presence of RPx in samples collected from herpetic lesions.
- New malignancy: a new cancer that appears during follow-up.
- Neurologic disorder: a problem affecting the brain, nerves, or spinal cord.
- Autoimmune disorder: a condition where the immune system attacks the body’s own tissues.
- Hematologic disorder: a blood-related problem.
- Herpetic infection: infection linked to herpes viruses.
RP3 and related RPx products
The trial title and summary refer to RP1, RP2, RP3, and the group name RPx products. In the source data, these products are grouped together for long-term safety follow-up.
The source material does not provide a deeper description of how RP3 works, so this article stays focused on the clinical trial goals and patient groups.
Key points for patients
- The available RP3 study is focused on safety after earlier treatment.
- It includes patients with several cancer types, especially melanoma-related conditions and liver cancer.
- The study is in Phase 3 and is already authorised.
- Researchers are mainly watching for delayed side effects and late health problems.